Technical Analysis for SOLTF - Sosei Group Corporation

Grade Last Price % Change Price Change
grade D 14.45 -9.74% -1.5600
SOLTF closed down 9.74 percent on Tuesday, July 21, 2020, on 7.56 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Down
Historical SOLTF trend table...

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 0.00%
Volume Surge Other 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Gapped Down Weakness 0.00%
Crossed Above 50 DMA Bullish -9.74%
Narrow Range Bar Range Contraction -9.74%
Wide Bands Range Expansion -9.74%
Gapped Up Strength -9.74%
Fell Below 50 DMA Bearish -0.14%
Older signals for SOLTF ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Sosei Group Corporation, a biopharmaceutical company, discovers, develops, and commercializes biopharmaceutical products worldwide. Its marketed products include Seebri/NVA237, an inhaled long-acting muscarinic antagonist indicated as a maintenance bronchodilator treatment for chronic obstructive pulmonary disease (COPD); Ultibro/QVA149, an inhalation capsule for the bronchodilator treatment of COPD; and NorLevo, an oral emergency contraceptive. The company's product pipeline consists of SO-1105, an antifungal agent, which is in Phase III clinical trial for the treatment of oropharyngeal candidiasis in immunocompromised patients; and APP13002 and APP13007, which are in pre-clinical stage for infectious eye diseases, such as cornea and conjunctivitis, and inflammation. It also develops JIT-2001 for cardiovascular disease and JIT-1007 for orphan diseases that are in pre-clinical stage; and discovers and develops pharmaceutical products targeting G protein-coupled receptors. In addition, the company is developing biopharmaceuticals for the treatment of Alzheimer's disease, schizophrenia, cancer, migraine, addiction, metabolic diseases, and other indications. The company has a strategic collaboration with PeptiDream Inc. Sosei Group Corporation was founded in 1990 and is headquartered in Tokyo, Japan.
Health Cancer Biopharmaceutical Pharmaceutical Pharmaceutical Products Inflammation Cardiovascular Disease Metabolic Diseases Chronic Obstructive Pulmonary Disease Alzheimer's Disease Respiratory Therapy Biopharmaceuticals Biopharmaceutical Products Chronic Lower Respiratory Diseases Orphan Diseases Schizophrenia Conjunctivitis Copd Combination Drugs Migraine Pulmonary Function Testing Treatment Of Alzheimer's Disease

Is SOLTF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 237.05
52 Week Low 8.03
Average Volume 476
200-Day Moving Average 0.0000
50-Day Moving Average 15.1325
20-Day Moving Average 18.3750
10-Day Moving Average 16.0170
Average True Range 1.5819
ADX 15.48
+DI 43.2090
-DI 55.1230
Chandelier Exit (Long, 3 ATRs ) 18.8343
Chandelier Exit (Short, 3 ATRs ) 16.7457
Upper Bollinger Band 24.3338
Lower Bollinger Band 12.4162
Percent B (%b) 0.17
BandWidth 64.8577
MACD Line -1.0487
MACD Signal Line -0.6083
MACD Histogram -0.4404
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 14.4500
Resistance 3 (R3) 14.4500 14.4500 14.4500
Resistance 2 (R2) 14.4500 14.4500 14.4500 14.4500
Resistance 1 (R1) 14.4500 14.4500 14.4500 14.4500 14.4500
Pivot Point 14.4500 14.4500 14.4500 14.4500 14.4500
Support 1 (S1) 14.4500 14.4500 14.4500 14.4500 14.4500
Support 2 (S2) 14.4500 14.4500 14.4500 14.4500
Support 3 (S3) 14.4500 14.4500 14.4500
Support 4 (S4) 14.4500